Should autologous HSCT be a first-line option in highly active MS? Commentary

Multiple Sclerosis Journal 2026 Open access

Read full text

Authors: Anna Karin Hedström

DOI: 10.1177/13524585261439675

Cited by: 1

References: 5

Fields of Study & Subjects

Multiple Sclerosis Research Studies Monoclonal and Polyclonal Antibodies Research Autoimmune Neurological Disorders and Treatments

References 5